“Me Too” Biotech Wrestling Suicide & Depression : Seelos Therapeutics
Seelos Therapeutics : Seelos Therapeutics is not looking to reinvent the wheel by any means. They are simply looking to administer Ketamine. A dissociative anesthetic, or “tranquilizer” prescribed to patients who depressed and suicidal patients. Ketamine a successful use history of over 50 years. In addition has a clear affect on human beings.
Seelos is looking to administer Ketamine through their SLS-002 (intranasal racemic ketamine). Their only competitor would be the established Johnson & Johnson product. Spravato, with estimates to produce nearly $400m in annual sales by 2029.
If Seelos’ product can grab just 20% of the market, they are looking at a huge drug.
But, they should grab well over 50% of the market and capture upside market that Johnson & Johnson’s Spravato simply can not.
As a result of, “in a small randomized trial, intranasal ketamine caused minimal dissociative effects, which, if replicated in larger trials, would give SLS-002 an advantage over Spravato.”
As compared to Spravato causing significant side-effects.
Furthermore, Spravato requires 2 hours of patient monitoring after taking the drug. Moreover, this is a gigantic cost albatross on Spravato’s use by patients and thus, revenue growth. If SLS-002 can avoid requiring 2 hours of patient monitoring, then not only will they grab the lion’s share of the market. But, furthermore they can grab a large untapped market. Since Spravato’s market is limited by needing 2 hours of patient monitoring.
Furthermore, initial results on SLS-002 have been extraodinrily promising. So we will have to keep our eyes on this biotechnology play.